^
    Back
    Association details:
    Biomarker:PD-1 overexpression
    Cancer:Cutaneous T-cell Lymphoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

    Published date:
    11/06/2019
    Excerpt:
    Unexpectedly, in pembrolizumab responders compared to non-responders, PD-1 expression levels were higher in multiple clusters of tumor cells and reactive T cells.
    DOI:
    10.1182/blood-2019-125315